Navigation Links
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:12/31/2007

rmal cell division). The contribution of the purine analog to the antitumor effect of TREANDA is under investigation but has not yet been determined.

The protocol for the TREANDA NHL pivotal trial received special protocol assessment (SPA) approval from the FDA in February 2006. The SPA process allows for FDA evaluation and acceptance of a clinical trial protocol, including trial size, clinical endpoints and/or data analysis. In September 2007, Cephalon submitted an NDA requesting approval of TREANDA for the treatment of patients with chronic lymphocytic leukemia (CLL), for which the FDA has granted priority review and orphan drug status.

Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from Astellas Pharma GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation Limited, under the trade name RIBOMUSTIN(R). In Germany, RIBOMUSTIN is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asia Pacific Rim countries.

About Cephalon Oncology

Cephalon Oncology is a strategic business unit focused on the development and commercialization of oncology products and resources for patients and healthcare providers. The Cephalon Oncology portfolio includes a number of promising investigational and marketed compounds. In addition to TREANDA, the Cephalon Oncology therapeutic portfolio in the United States includes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United States for the treatment of patients with relapsed or refractory acute promyelocytic leukemia, and CEP-701, an oral small molecule inhibitor of tyrosine kinases including FLT-3, TRK and JAK-2, in phase 3 development for acute myeloid leukemia.

In Eur
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
(Date:5/20/2015)... 2015  Health eCareers, the healthcare industry,s online ... job seekers looking for the flexibility of short-term ... and online tool dedicated exclusively to temporary and ... SHIFT enables employers to quickly find and hire ... diem and other temporary positions, eliminating the time ...
(Date:5/20/2015)...  Cypher Genomics, Inc., a leading genome informatics ... to apply Cypher,s Coral TM technology to ... response to innovative medicines. The information generated from ... access to the right medicine at the right ... and potentially inform new companion diagnostics.  ...
(Date:5/20/2015)... CA, Mulhouse, France, Cambridge, MA (PRWEB) May 20, ... provider of high quality transporter assay services for ... and Pharmacology, and Rhenovia Pharma, a world leader ... neurotransmission using Translational Quantitative Systems Pharmacology supported by ... partnership agreement. , The agreement allows both companies ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... , ATLANTA, Aug. 5 GeoVax Labs, Inc. ... today announced updates on its ongoing and planned human clinical trials. ... areas of focus for our HIV/AIDS vaccine - preventative and therapeutic," ... Labs, Inc. "The results of the early Phase 1 clinical ...
... , SAINT JOHN, New Brunswick, ... between nuclear reactors and thyroid disease near NYC was made ... festival is held just downstream from Indian Point, the oldest ... commitment to a clean environment, it stepped up by permitting ...
... 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a ... with UK-based Scancell Ltd., the operating company of ... cancer and infectious disease vaccines. This research agreement ... delivery system for Scancell,s novel ImmunoBody(R) DNA vaccines. ...
Cached Biology Technology:GeoVax Labs, Inc. Provides Clinical Studies Update 2GeoVax Labs, Inc. Provides Clinical Studies Update 3GeoVax Labs, Inc. Provides Clinical Studies Update 4GeoVax Labs, Inc. Provides Clinical Studies Update 5TSH Testing Raises Awareness of Importance of Thyroid Health 2ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery 2
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/10/2015)... Sweden , May 11, 2015 ... fingerprint sensors FPC1025 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of + 1 000 MSEK ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... Beyond the simple stream of one-letter characters in the ... In order to decipher this level of architecture, scientists ... detect copy number variants (CNVs)--defined as large deletions and ... the journal Genome Research --were used to create ...
... behind the dramatic increase in testicular cancer, now ... men, is the focus of a five-year, $5.5 ... Public Health researcher Tongzhang Zheng. , Testicular cancer ... will provide important information on possible environmental, genetic ...
... Helping to change scientists' thinking about how the heart is ... of stem cell that is the precursor to at least ... cardiac progenitor cell gives rise to both myocardial cells, which ... heart, and to the vascular smooth muscle cells that line ...
Cached Biology News:New technology used to construct the first map of structural variation in the human genome 2Getting to the heart of the heart 2Getting to the heart of the heart 3
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
...
... the first biological reagent that ... and not just by inhibiting ... anti-mycoplasma agent that can be ... directly. The cytotoxicity of Mynox ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: